Abbott Laboratories

ABT · NYSE · USD

Financials

Annual

StatisticsIncome statementBalance sheetCash flowDividendsSegments

Valuation and market statistics · USD millions unless noted · ratios on the twelve months ending at each period

Line item	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001	FY2000	FY1999	FY1998	FY1997	FY1996	FY1995	FY1994	FY1993	FY1992	FY1991	FY1990	FY1989	FY1988	FY1987	FY1986	FY1985
Valuation
Market cap	$217,863	$196,184	$191,088	$191,427	$248,869	$193,610	$153,593	$127,900	$100,916	$67,920	$79,414	$67,892	$59,339	$49,413	–	–	–	–	–	–	–	–	–	$28,066	$38,868	$33,716	$25,095	$33,865	$22,839	$17,747	$14,889	$11,907	$11,042	$11,437	$13,168	$8,727	$6,826	$4,834	$4,898	$4,771	$3,574
Enterprise value	$224,632	$203,729	$199,906	$199,422	$258,093	$206,571	$168,765	$143,578	$119,431	$71,330	$82,405	$71,375	$57,898	$54,807	–	–	–	–	–	–	–	–	–	$33,522	$45,444	$34,115	$26,605	$36,581	$25,299	$19,940	$16,059	$12,652	$11,814	$12,346	$13,777	$9,491	$7,259	$5,094	$5,256	$5,179	$3,702
P/E (TTM) at period end	33.52×	14.64×	33.52×	27.72×	35.34×	43.28×	41.90×	54.36×	215.63×	48.76×	18.04×	29.87×	23.20×	8.35×	–	–	–	–	–	–	–	–	–	10.05×	25.07×	12.10×	10.26×	14.51×	10.99×	9.43×	8.82×	7.85×	7.89×	9.23×	12.09×	9.04×	7.94×	6.43×	7.74×	8.83×	7.68×
P/S (TTM) at period end	4.91×	4.68×	4.76×	4.39×	5.78×	5.59×	4.81×	4.18×	3.68×	3.26×	3.89×	3.35×	3.02×	2.59×	–	–	–	–	–	–	–	–	–	1.59×	2.39×	2.45×	1.90×	2.71×	1.92×	1.61×	1.49×	1.30×	1.31×	1.46×	1.91×	1.42×	1.27×	0.98×	1.12×	1.25×	1.06×
P/B at period end	4.18×	4.12×	4.95×	5.22×	6.95×	5.91×	4.94×	4.19×	3.27×	3.31×	3.74×	3.15×	2.36×	1.85×	–	–	–	–	–	–	–	–	–	2.63×	4.29×	3.93×	3.38×	5.93×	4.57×	3.68×	3.39×	2.94×	3.00×	3.42×	4.11×	3.08×	2.50×	1.96×	2.34×	2.68×	1.91×
EV / EBITDA (TTM)	23.68×	24.95×	25.78×	20.74×	26.03×	31.53×	30.08×	30.23×	45.76×	18.63×	22.05×	20.29×	18.91×	20.13×	–	–	–	–	–	–	–	–	–	7.99×	14.84×	8.07×	6.69×	9.37×	7.07×	6.04×	5.44×	4.77×	4.91×	6.32×	7.12×	5.39×	4.75×	–	–	–	–
EV / Sales (TTM)	5.07×	4.86×	4.98×	4.57×	5.99×	5.97×	5.29×	4.70×	4.36×	3.42×	4.04×	3.53×	2.95×	2.88×	–	–	–	–	–	–	–	–	–	1.90×	2.79×	2.48×	2.02×	2.93×	2.13×	1.81×	1.60×	1.38×	1.41×	1.57×	2.00×	1.54×	1.35×	1.03×	1.20×	1.36×	1.10×
Returns
Return on equity	12.5%	28.1%	14.8%	18.8%	19.7%	13.6%	11.8%	7.7%	1.5%	6.8%	20.8%	10.6%	10.2%	22.1%	19.3%	20.4%	24.8%	27.9%	20.3%	12.2%	23.4%	22.6%	21.1%	26.2%	17.1%	32.5%	32.9%	40.9%	41.6%	39.0%	38.4%	37.5%	38.1%	37.0%	34.0%	34.1%	31.5%	30.5%	30.2%	30.4%	24.9%
Return on invested capital	10.5%	12.3%	11.6%	15.5%	16.0%	10.5%	8.8%	6.4%	0.5%	9.4%	9.3%	7.0%	7.3%	–	4.5%	13.0%	16.2%	18.5%	13.4%	12.6%	18.7%	16.9%	12.1%	14.6%	9.9%	26.9%	25.0%	26.4%	27.0%	26.3%	30.0%	31.1%	30.6%	25.5%	28.8%	27.9%	27.8%	28.8%	27.7%	26.5%	24.7%
Dividend yield	1.9%	2.0%	1.9%	1.7%	1.3%	1.3%	1.5%	1.5%	1.8%	2.3%	1.8%	2.0%	1.5%	6.4%	–	–	–	–	–	–	–	–	–	5.1%	3.3%	3.4%	4.0%	2.6%	3.5%	4.1%	4.4%	5.1%	5.0%	4.3%	3.1%	4.0%	4.4%	–	–	–	–
Financial health
Current ratio	1.58×	1.67×	1.64×	1.63×	1.85×	1.72×	1.44×	1.62×	2.26×	4.02×	1.54×	1.30×	2.02×	2.36×	1.54×	1.29×	1.79×	1.47×	1.54×	0.94×	1.54×	1.57×	1.35×	1.30×	1.06×	1.72×	1.42×	1.12×	1.00×	1.03×	1.12×	1.12×	1.16×	1.16×	1.30×	1.23×	1.52×	1.63×	1.45×	1.45×	2.13×
Debt / equity	0.25×	0.30×	0.38×	0.46×	0.50×	0.57×	0.58×	0.63×	0.90×	1.01×	0.28×	0.16×	0.13×	0.69×	0.53×	0.64×	0.50×	0.56×	0.58×	0.88×	0.46×	0.47×	0.46×	0.60×	0.80×	0.18×	0.30×	0.54×	0.54×	0.48×	0.34×	0.26×	0.31×	0.31×	0.21×	0.28×	0.16×	0.34×	0.42×	0.50×	0.30×
Effective tax rate	22.9%	(91.1%)	14.1%	16.5%	13.9%	10.0%	9.6%	18.8%	84.2%	24.8%	18.1%	31.7%	2.6%	207.7%	8.9%	19.0%	20.1%	19.2%	19.3%	24.6%	27.0%	23.0%	26.3%	23.9%	17.7%	27.0%	28.0%	28.0%	29.0%	29.5%	29.5%	30.0%	28.0%	28.7%	29.5%	28.5%	28.0%	28.7%	32.5%	34.0%	33.0%
Share count
Diluted shares outstanding	1,748	1,748	1,749	1,764	1,789	1,786	1,781	1,770	1,749	1,483	1,506	1,527	1,574	1,592	1,567	1,556	1,555	1,561	1,560	1,537	1,564	1,571	1,572	1,573	1,566	1,566	1,558	1,561	1,575	1,582	1,595	1,624	1,658	1,674	1,701	1,725	1,755	1,790	1,807	1,864	1,861

StatisticsIncome statementBalance sheetCash flowDividendsSegments

Income statement · USD millions

Line item	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001	FY2000	FY1999	FY1998	FY1997	FY1996	FY1995	FY1994	FY1993	FY1992	FY1991	FY1990	FY1989	FY1988	FY1987	FY1986	FY1985
Revenue and gross profit
Revenue	$48,229	$44,328	$41,950	$40,109	$43,653	$43,075	$34,608	$31,904	$30,578	$27,390	$20,853	$20,405	$20,247	$19,657	$19,050	$21,407	$35,167	$30,765	$29,528	$25,914	$22,476	$22,338	$19,680	$19,681	$17,685	$16,285	$13,746	$13,178	$12,478	$11,883	$11,013	$10,012	$9,156	$8,408	$7,852	$6,877	$6,159	$5,380	$4,937	$4,388	$3,808	$3,360
Cost of revenue	($20,726)	($19,319)	($18,706)	($17,975)	($19,142)	($18,537)	($15,003)	($13,231)	($12,706)	($12,337)	($9,024)	($8,747)	($9,218)	($9,193)	($8,899)	($10,017)	($14,665)	($13,209)	($12,612)	($11,422)	($9,634)	($10,467)	($8,884)	($9,473)	($8,506)	($7,748)	($6,239)	($5,977)	($5,394)	($5,046)	($4,732)	($4,326)	($3,994)	($3,685)	($3,078)	($2,761)	($2,554)	($2,249)	($2,082)	($1,858)	($1,669)	($1,539)
Gross profit	$27,503	$25,009	$23,244	$22,134	$24,511	$24,538	$19,605	$18,673	$17,872	$15,053	$11,829	$11,658	$11,029	$10,464	$10,151	$11,390	$20,502	$17,555	$16,916	$14,492	$12,842	$11,871	$10,796	$10,207	$9,178	$8,537	$7,507	$7,200	$7,083	$6,838	$6,281	$5,686	$5,162	$4,723	$4,774	$4,116	$3,604	$3,130	$2,855	$2,530	$2,139	$1,821
Operating expenses
Research and development	($3,302)	($2,942)	($2,844)	($2,741)	($2,888)	($2,742)	($2,420)	($2,440)	($2,300)	($2,260)	($1,447)	($1,405)	($1,345)	($1,371)	($1,461)	($1,512)	($3,724)	($2,744)	($2,689)	($2,506)	($2,226)	($1,811)	($1,697)	($1,733)	($1,562)	($1,578)	($1,351)	($1,194)	($1,222)	($1,302)	($1,205)	($1,073)	($964)	($881)	–	–	–	–	–	–	–	–
Selling, general and administrative	($15,093)	($12,332)	($11,697)	($10,949)	($11,248)	($11,324)	($9,696)	($9,765)	($9,744)	($9,182)	($6,736)	($6,785)	($6,530)	($6,372)	($6,735)	($7,365)	($10,376)	($8,406)	($8,436)	($7,408)	($6,280)	($5,410)	($4,922)	($5,051)	($3,979)	($3,735)	($2,894)	($2,857)	($2,744)	($2,685)	($2,460)	($2,231)	($2,054)	($1,988)	($2,821)	($2,180)	($1,842)	($1,602)	($1,482)	($1,280)	($1,061)	($928)
Total operating expenses	($20,738)	($16,956)	($16,419)	($15,656)	($16,149)	($16,113)	($14,248)	($14,141)	($14,222)	($13,489)	($8,803)	($8,791)	($8,430)	($8,331)	($8,791)	($9,761)	($14,414)	($11,320)	($11,222)	($9,914)	($8,506)	($7,221)	($6,619)	($7,233)	($6,026)	($6,643)	($4,107)	($4,051)	($3,965)	($3,987)	($3,664)	($3,303)	($3,018)	($2,799)	($3,248)	($2,559)	($2,198)	($1,909)	($1,753)	($1,524)	($1,260)	($1,084)
Total costs and expenses	($41,464)	($36,275)	($35,125)	($33,631)	($35,291)	($34,650)	($29,251)	($27,372)	($26,928)	($25,826)	($17,827)	($17,538)	($17,648)	($17,524)	($17,690)	($19,778)	($29,079)	($24,529)	($23,834)	($21,336)	($18,140)	($17,688)	($15,503)	($16,707)	($14,533)	($14,391)	($10,345)	($10,028)	($9,360)	($9,033)	($8,396)	($7,629)	($7,012)	($6,484)	($6,326)	($5,320)	($4,753)	($4,159)	($3,835)	($3,382)	($2,929)	($2,623)
Operating income	$6,765	$8,053	$6,825	$6,478	$8,362	$8,425	$5,357	$4,532	$3,650	$1,564	$3,026	$2,867	$2,599	$2,133	$1,360	$1,629	$6,088	$6,236	$5,694	$4,579	$4,336	$4,649	$4,177	$2,974	$3,152	$1,894	$3,401	$3,149	$3,118	$2,850	$2,617	$2,383	$2,144	$1,924	$1,526	$1,557	$1,406	$1,221	$1,102	$1,006	$879	$737
Earnings
EBITDA	–	$9,487	$8,165	$7,755	$9,616	$9,916	$6,552	$5,610	$4,750	$2,610	$3,829	$3,738	$3,517	$3,061	$2,723	$3,024	$7,295	$7,447	$6,746	$5,651	$5,895	$6,008	$5,466	$4,101	$4,196	$3,062	$4,228	$3,977	$3,902	$3,578	$3,303	$2,949	$2,655	$2,408	$1,954	$1,936	$1,762	$1,528	–	–	–	–
Interest income	–	$308	$344	$385	$183	$43	$46	$94	$105	$124	$99	$105	$77	$67	$59	$65	$105	$138	$201	$137	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest expense	($942)	($493)	($559)	($637)	($558)	($533)	($546)	($670)	($826)	($904)	($431)	($163)	($150)	($145)	($320)	($359)	($553)	($520)	($528)	($593)	($416)	($241)	($200)	($146)	($205)	($234,759)	($23)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pre-tax income	$6,562	$8,466	$7,013	$6,664	$8,306	$8,211	$4,968	$4,077	$2,873	$2,231	$1,413	$3,183	$2,518	$2,041	($220)	$1,236	$5,713	$7,194	$5,856	$4,470	$2,276	$4,620	$4,126	$3,734	$3,673	$1,883	$3,816	$3,397	$3,241	$2,950	$2,670	$2,395	$2,167	$1,943	$1,739	$1,544	$1,351	$1,194	$1,055	$937	$819	$694
Income tax expense	($1,861)	($1,942)	$6,389	($941)	($1,373)	($1,140)	($497)	($390)	($539)	($1,878)	($350)	($577)	($797)	($53)	$457	($110)	($1,087)	($1,448)	($1,122)	($863)	($560)	($1,248)	($950)	($981)	($880)	($333)	($1,030)	($951)	($907)	($855)	($788)	($707)	($650)	($544)	($500)	($456)	($385)	($334)	($303)	($305)	($278)	($229)
Net income	$4,701	$6,524	$13,402	$5,723	$6,933	$7,071	$4,495	$3,687	$2,368	$477	$1,400	$4,423	$2,284	$2,576	$5,917	$4,714	$4,626	$5,746	$4,881	$3,606	$1,717	$3,372	$3,236	$2,753	$2,794	$1,550	$2,786	$2,446	$2,334	$2,079	$1,882	$1,689	$1,517	$1,399	$1,239	$1,089	$966	$860	$752	$633	$540	$465
Per share
Diluted EPS (GAAP)	$2.69	$3.72	$7.64	$3.26	$3.91	$3.94	$2.50	$2.06	$1.33	$0.27	$0.94	$2.92	$1.49	$1.62	$3.72	$3.01	$2.96	$3.69	$3.12	$2.31	$1.12	$2.16	$2.06	$1.75	$1.78	$0.99	$1.78	$1.57	$1.49	$1.33	$1.19	$1.06	$0.93	$0.84	$0.74	$0.64	$0.56	$0.49	$0.42	$0.35	$0.29	$0.25
Basic EPS (GAAP)	$2.70	$3.73	$7.67	$3.28	$3.94	$3.97	$2.52	$2.07	$1.34	$0.27	$0.94	$2.94	$1.50	$1.64	$3.76	$3.03	$2.98	$3.71	$3.16	$2.34	$1.12	$2.17	$2.07	$1.76	$1.79	$1.00	$1.80	$1.59	$1.52	$1.35	$1.21	$1.06	$0.93	$0.84	$0.74	$0.64	$0.56	$0.49	$0.42	$0.35	$0.29	$0.25
Basic shares outstanding	1,742	1,741	1,740	1,740	1,753	1,775	1,773	1,768	1,758	1,740	1,477	1,496	1,516	1,558	1,575	1,557	1,546	1,547	1,545	1,543	1,530	1,552	1,561	1,563	1,561	1,550	1,548	1,537	1,537	1,552	1,555	1,591	1,624	1,658	1,674	1,701	1,725	1,755	1,790	1,807	1,864	1,861
Margins
Gross margin	57.0%	56.4%	55.4%	55.2%	56.1%	57.0%	56.6%	58.5%	58.4%	55.0%	56.7%	57.1%	54.5%	53.2%	53.3%	53.2%	58.3%	57.1%	57.3%	55.9%	57.1%	53.1%	54.9%	51.9%	51.9%	52.4%	54.6%	54.6%	56.8%	57.5%	57.0%	56.8%	56.4%	56.2%	60.8%	59.8%	58.5%	58.2%	57.8%	57.7%	56.2%	54.2%
Operating margin	14.0%	18.2%	16.3%	16.2%	19.2%	19.6%	15.5%	14.2%	11.9%	5.7%	14.5%	14.1%	12.8%	10.9%	7.1%	7.6%	17.3%	20.3%	19.3%	17.7%	19.3%	20.8%	21.2%	15.1%	17.8%	11.6%	24.7%	23.9%	25.0%	24.0%	23.8%	23.8%	23.4%	22.9%	19.4%	22.6%	22.8%	22.7%	22.3%	22.9%	23.1%	21.9%
Net margin	9.7%	14.7%	31.9%	14.3%	15.9%	16.4%	13.0%	11.6%	7.7%	1.7%	6.7%	21.7%	11.3%	13.1%	31.1%	22.0%	13.2%	18.7%	16.5%	13.9%	7.6%	15.1%	16.4%	14.0%	15.8%	9.5%	20.3%	18.6%	18.7%	17.5%	17.1%	16.9%	16.6%	16.6%	15.8%	15.8%	15.7%	16.0%	15.2%	14.4%	14.2%	13.8%

Analyst consensus

Buy43 analysts

Bearish · 0 · Hold · 9 · Bullish · 34

Earnings history

	EPS	Estimate
Q4 2024	$1.34	$1.34	Match
Q1 2025	$1.09	$1.07	Beat
Q2 2025	$1.26	$1.26	Match
Q3 2025	$1.30	$1.30	Match
Q4 2025	$1.50	$1.50	Match
Q1 2026	$1.15	$1.14	Beat
Q2 2026	$1.31	$1.28	Beat
Q3 2026	$1.42	$1.42	Match

Peers

Company overview

IPO dateMar 17, 1980

CEORobert Ford

Employees115,000

SectorHealthcare

IndustryMedical - Devices

CountryUS

ExchangeNew York Stock Exchange

Websitewww.abbott.com

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.